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PURPOSE. To characterize contrast sensitivity (CS) across the
visual field for two achromatic spatial–temporal frequencies in
21 families with Stargardt disease (STGD) and to correlate
psychophysical impairment with patterns of change in multi-
focal electroretinography (mfERG).
METHODS. Twenty-seven eyes from patients with STGD, 16 eyes
from asymptomatic relatives, and 44 age-matched control eyes
were included. Chromatic CS function was assessed by com-
paring protan, deutan, and tritan (Cambridge Color Test; Cam-
bridge Research Systems Ltd., Rochester, UK) and anomalo-
scope measures (IF-2; Roland Consult, Wiesbaden, Germany).
Achromatic CS measures were obtained with custom-made
software in nine locations by using randomly interleaved stair-
cases. The first task—low spatial frequency (LSF)—matched
the known frequency-doubling method that is believed to ac-
tivate the magnocellular pathway preferentially. The second
included an intermediate spatial frequency (ISF, 3.5 cyc/deg).
mfERGs (RETIscan; Roland Consult) were also obtained. Rela-
tives were screened for ABCA4 mutations by ABCR400 mi-
croarray and direct sequencing.
RESULTS. Central impairment of achromatic and chromatic CS
(along the three isolation axes) was observed in STGD. LSF and
ISF tasks revealed significant and widespread dysfunction in
patients and their morphologically unaffected relatives, 80% of
whom were found to be ABCA4 mutation carriers. Significant
reduction of P1 amplitudes was also observed in both groups.
CONCLUSIONS. CS function is impaired in patients with STGD at
distinct spatial–temporal frequencies, which, in addition to the
color vision deficits, suggests dual impairment of the magno-
parvocellular pathways. STGD morphologically unaffected car-
riers may show patterns of psychophysical dysfunction that are
mirrored by abnormal mfERG responses. (Invest Ophthalmol
Vis Sci. 2008;49:1191–1199) DOI:10.1167/iovs.07-1051
Stargardt macular dystrophy (STGD; OMIM 248200; http://www.ncbi.nlm.nih.gov/Omim/ Online Mendelian Inheri-
tance in Man; National Institutes of Health, Bethesda, MD),1
accounts for 7% of all retinal dystrophies and affects approxi-
mately 1 in 10,000 people, with a typical onset during child-
hood and a predominantly autosomal recessive inheritance1–5
Bilateral retinal atrophic lesions may have a “beaten-metal”
appearance, and the pattern of distribution, number, and shape
of the flecks is variable and can change over time.4–7 Accumu-
lation of lipofuscin-like material in the retinal pigment epithe-
lial (RPE) cells is thought to be the cause of diffuse blockage of
choroidal filling on fluorescein angiography (“choroidal si-
lence”), which often occurs in these patients.8–10
In 1993, Kaplan et al.2 mapped the locus for STGD/FFM
(fundus flavimaculatus) to the short arm of chromosome 1 and
ABCA4, a photoreceptor-specific adenosine triphosphate
(ATP)-binding cassette transporter, was subsequently charac-
terized. Several groups performed mutation analysis of ABCA4
in STGD/FFM patients, and more than 490 sequence variations
have recently been identified.11–13 Such high allelic heteroge-
neity within the 50 exons of ABCA4 makes it difficult to
predict the disease-causing variants. It is likely that the wide
variation in retinal phenotype within families (age of onset,
disease severity, pattern of lipofuscin accumulation, ERG re-
sults, visual acuity) may be explained by different combinations
of ABCA4 mutations segregating within a single family5–8,14 Fur-
thermore, mutations in this gene have also been implicated in
other macular dystrophies.15–18
Given that STGD-FFM involves symptoms mostly related to
cone dysfunction, it was surprising that first reports of ABCA4
expression found its presence in rod but not in cone photore-
ceptors.19 However, later, it was shown by immunofluores-
cence microscopy and Western blot analysis that ABCA4 is
expressed in foveal and peripheral cones and in rod photore-
ceptors.20 In accordance with ABCA4 expression in cones and
with the main clinical manifestations, Scholl et al.21 found that
long (L) and M (middle)-wavelength cone driven ERGs exhibit
phase and amplitude alterations in STGD.
The main intent of the present study was to establish topo-
graphical characterization of psychophysical performance in
patients with STGD and their morphologically unaffected rel-
atives, in which concerns contrast sensitivity within distinct
spatial frequency channels. We further sought to establish the
phenotyping value of this strategy in members of families with
STGD and their correlation with multifocal electrophysiologi-
cal (mfERG) measures. We have also quantified L-, M- and
S-cone function using a psychophysical method that has al-
ready been shown to be useful in understanding structure–
function correlations in other macular dystrophies, namely
Best disease.22 Of importance, we have used the above-men-
tioned methods to study clinically and genetically character-
ized asymptomatic relatives, as revealed by normal ophthalmic
examination. The goal was to test the possibility of subtle
visual impairment in putative carriers, whose carrier state was
assessed.
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METHODS
Characterization of the Clinical Group
Twenty seven patients with Stargardt (n  27 eyes; mean age: 23.9 
13.5 [SD] years, range: 7–61) and 16 morphologically unaffected rel-
atives with normal ophthalmic examination findings (n  16 eyes;
mean age: 29.3  16.2 years, range: 8–66) from 21 families were
included in the study and compared with an age-matched group of 22
normal control subjects (n  44 eyes, mean age: 28.0  15.9 years,
range: 6–69 years). Analysis of variance showed no significant age
difference between groups (F test; P  0.118 for normal versus rela-
tives, P  0.534 for normal versus STGD group, and P  0.385 for
relatives versus STGD group).
The clinical ophthalmic examination performed in all participants
included best-corrected visual acuity (VA) obtained by postcycloplegic
manifest refraction on Snellen charts, slit-lamp examination, fluores-
cein angiography and dilated fundus examination by direct and indi-
rect ophthalmoscopy. We staged our patients according to the criteria
for increasing severity described by Scholl et al.21 Only subjects pre-
senting no other eye diseases were included. The age of onset was
defined as the age at which decreased VA was first noted. Clinical data
of patients with STGD are shown in Table 1.
Informed consent was obtained from all subjects after explanation of
the objectives and possible consequences of the study, in strict accor-
dance with the institutional guidelines defined by the ethics committee of
the Faculty of Medicine of Coimbra. The research was conducted in
accordance with the tenets of the Declaration of Helsinki.
Psychophysics
Color Psychophysical Tasks. All subjects underwent
color vision testing both for the Rayleigh or Moreland equations by
TABLE 1. Clinical Characteristics of Patients with Stargardt Disease and Their Relatives
Family Subjects Sex Phenotype CFC
Age
(y)
Onset
(y)
Duration
(y)
VA
Color VisionOD OS
1 CAP M Stargardt Severe 42 7 35 1/10 1/10 PT
PCP M Stargardt Severe 38 14 24 1/10 0.5/10 DT
ELP M Stargardt Severe 33 11 22 1/10 1/10 PT
ARP M Relative (father) No changes 66 — — 10/10 10/10 Normal
2 ACO F Stargardt Mild 8 5 3 8/10 6/10 Normal
TMO M Stargardt Severe 12 8 4 1/10 8/10 T
CAO F Relative (sister) Subtle* 8 — — 10/10 10/10 Normal
3 DMB M Stargardt Moderate 16 6 10 1.6/10 1.6/10 P
GMB M Relative (brother) No changes 19 — — 10/10 10/10 Normal
4 MJG M Stargardt Severe 34 6 28 FC FC NP
MAS F Relative (sister) No changes 36 — — 10/10 10/10 Normal
5 MRA F Stargardt Severe 17 12 5 1/10 1/10 PT
MCA F Relative (mother) No changes 40 — — 10/10 10/10 Normal
6 MCB F Stargardt Moderate 20 14 6 1/10 1/10 P
LCB M Relative (brother) No changes 30 — — 10/10 10/10 D
7 RCG M Stargardt Moderate 24 11 13 0.5/10 0.5/10 PT
VCG F Relative (sister) No changes 17 — — 10/10 10/10 P
8 RMF M Stargardt Moderate 11 9 2 0.5/10 1/10 PT
JMF M Relative (brother) No changes 18 — — 10/10 10/10 Normal
9 RFF M Stargardt Moderate 9 7 2 0.5/10 1/10 Normal
DRN F Relative (mother) No changes 36 — — 10/10 10/10 P
10 MCR M Stargardt Moderate 27 24 3 1.2/10 1.2/10 PT
SCR F Relative (sister) No changes 23 — — 10/10 10/10 T
11 JGK M Stargardt Severe 29 9 20 FC FC NP
AGK F Relative (sister) No changes 31 — — 10/10 10/10 T
12 LMO M Stargardt Moderate 43 43 0 1/10 3/10 NP
13 CAO M Stargardt Moderate 61 30 31 0.5/10 0.5/10 T
MGO M Stargardt Moderate 40 30 10 6/10 8/10 P
JLO M Relative (brother) Subtle* 54 — — 10/10 10/10 PT
14 PRL F Stargardt Severe 11 7 4 1/10 1/10 PT
POL F Stargardt Severe 11 7 4 1/10 1/10 PT
GBR M Relative (father) No changes 39 — — 8/10 6/10 Normal
15 PGP F Stargardt Moderate 14 9 5 1/10 1/10 NP
16 ACA F Stargardt Moderate 32 27 5 1/10 1/10 PT
17 JGF M Stargardt Moderate 30 29 1 2.5/10 1.6/10 DT
CGF M Stargardt Moderate 25 25 0 3/10 FC PT
18 JMD M Stargardt Mild 10 9 1 2/10 2/10 T
CMD F Relative (sister) No changes 8 — — 10/10 10/10 Normal
19 ZMC F Stargardt Moderate 25 17 8 2/10 2/10 D
20 TCC M Stargardt Mild 7 1 6 1/10 1/10 PDT
MLC F Relative (mother) No changes 34 — — 10/10 10/10 Normal
21 CRG M Stargardt Mild 16 9 7 0.5/10 2/10 T
BRG F Relative (sister) No changes 11 — — 10/10 10/10 Normal
Data include gender, phenotype, central fundus changes (CFC), age at examination, age of onset, duration of disease, VA of the right (OD)
and left (OS) eyes, and color vision (CV) results from anomaloscope testing. CFC: mild  normal to diffuse foveal reflex, subtle pigment mottling
of the macular RPE, tapetal sheen or beaten-metal reflex; moderate  pronounced hyper- and hypopigmentation of the macular RPE, bull’s-eye
atrophy; severe  widespread confluent areas of RPE and/or choroidal atrophy; FC, visual acuity reduced to finger counting; P, protanomalous;
D, deuteranomalous; T, tritanomalous; NP, the subject could not perform the test.
* Siblings CAO and JLO had subtle changes in the fundus that did not fulfill the criteria for Stargardt disease.
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means of a anomaloscope (IF-2; Roland Consult, Wiesbaden, Ger-
many; Table 1).
Whenever possible, patients (n  9) were also tested for the three
main cone-confusion axes, simultaneously and in an interleaved man-
ner,22 by modulating chromaticity in CIE 1976 uv color space, using
a slightly modified version of the Cambridge Color Test (Cambridge
Research Systems Ltd. [CRS], Rochester, UK). Subjects looked monoc-
ularly at a screen with a pattern of disks of various sizes and luminance
with superimposed chromatic contrast defining a Landolt-like
C-shaped ring. Subjects performed this test monocularly with the
better eye and were instructed to indicate the gap position, whereas
the chromaticity of the Landolt C was adjusted according to the
staircase procedure. Psychophysical thresholds were assessed simulta-
neously through three parallel randomly interleaved staircases.23,24
Maximum and minimum excursion were 0.11 and 0.002 units in uv
color space, respectively. Each staircase was composed of 11 reversals,
and the mean of the last 7 reversals was taken as the threshold
estimate. Viewing distance was 56 cm, and the Landolt-like C-shaped
ring had the following dimensions: gap size, 5.14°; outer diameter,
24.43°; and inner diameter, 12.25°.
CS Achromatic Psychophysical Tasks. CS was assessed
independently for each location (up to 20° of the visual field) in a
randomly interleaved manner, with several staircases running in paral-
lel at each position.
Two different types of vertically oriented sinusoidal gratings were
used: LSF, 0.25 cycles per degree (cyc/deg) grating stimuli, flickering at
25 Hz, mimicking the frequency-doubling method, to characterize
magnocellular function25,26; and ISF, 3.5 cyc/deg static stimuli. Grating
stimuli were generated from a graphics card (CRS/VSG 2/5; CRS) and
displayed on a gamma-corrected 21-in. color monitor (frame rate 100
Hz; Trinitron GDM-F520; Sony, Tokyo, Japan) at a viewing distance of
36 cm. Mean background luminance was 61.7 and 51 cd/m2 for LSF
and ISF conditions, respectively.
Luminance modulation of the stimulus was expressed according to
Michelson luminance contrast (%) 100  (Lmax  Lmin)/(Lmax  Lmin).
Staircases were implemented by means of an adaptive logarithmic
strategy and were run for a total of four reversals, with the contrast of
the last two reversals being averaged to estimate contrast threshold.
The results were expressed in decibels units, dB  20  log (1/c), with
contrast (c) measured as a percentage.
This perimetric test was performed monocularly on the better eye.
The subjects were instructed to fixate a black square (1°  1°) in the
center of the screen and report the presence of vertical “striped”
targets (detection task) by means of a button press. Stimulus duration
was 200 ms, and ISI (interstimulus interval) was jittered between 2300
and 2800 seconds. Participants’ reliability was evaluated by the inclu-
sion of false-positive and -negative “catch trials,” and all results with
false-positive and -negative errors  33% were excluded, according to
standard criteria.27 Fixation loss was monitored by means of eye-
tracking methodology (infrared CRS monitoring device).
For the analyses of CS eccentricity dependence, three zones were
defined: zone 0, the 5° central region; zone 1 comprises locations at 5°
to 10° eccentricity; and zone 2 corresponds to locations at 10° and 20°
eccentricity (for details, see Fig. 3A).
Electrophysiological Recordings
We recorded mfERG by using DTL fiber electrodes, after 10 minutes of
light adaptation and pupil dilation with tropicamide (RETIscan System;
Roland Consult). Pupil diameter after dilation was, on average,7 mm.
The stimulus consisted of 61 hexagons, covering 30° of visual field
and presented on a 20-in. monitor at a viewing distance of 33 cm.
Refractive errors were corrected for the viewing distance. The hexa-
gon areas increased with eccentricity to compensate differences in
cone density across the retina (leading to a fourfold size change). Each
hexagon was temporally modulated between light and dark (frame
rate: 60 Hz; maximum luminance: 120 cd  m2). Observers were
instructed to fixate a small black cross in the center of the stimulus.
Fixation was checked by means of online video-monitoring during the
8 minutes lasting recording sessions and high-amplitude artifacts
were automatically eliminated. Data for three of the patients with
STGD were excluded from the statistical analysis, either because of
their very low signal-to-noise responses or unstable fixation. To im-
prove fixation stability, sessions were broken into 47-second segments,
and eight trials were recorded in total. Signals were amplified with a
gain of 100.000 and band-pass filtered (5–300 Hz). The surface elec-
trode impedance was less than 10 k. First-order kernels were ana-
lyzed because of their closer correlation with the function of the outer
retina and to avoid temporal adaptation mechanisms that are generally
considered to influence higher-order kernel analyses.28 The local re-
sponses obtained were divided by the respective stimulus area to
obtain the density-normalized response (nV/deg2). For each hexagon,
the amplitude of P1 (defined as the difference between N1 and P1
components) was calculated, and the implicit time of the P1 compo-
nent determined. To evaluate eccentricity dependence between group
differences of the local ERG responses, we obtained averaged re-
sponses across five concentric rings around the fovea.
ABCA4 Gene Mutation Detection
Relatives were screened for variants of the 50 exons of the ABCA4
gene by means of the ABCR400 microarray, according to a procedure
described by Jaakson et al.29 All genotyping results were confirmed by
direct sequencing. The exons in which their affected STGD family
member(s) were found to have any mutation were further sequenced.
Genomic DNA was extracted from peripheral blood samples with
an automated DNA extractor (BioRobot EZ1; Qiagen, Valencia, CA).
The primers were as described elsewhere.30 Sequencing reactions
were performed with a four-dye terminator cycle sequencing ready-
reaction kit (BigDye Terminator ver. 1.1, Applied Biosystems, Inc.
[ABI], Foster City, CA), and the sequence products were purified and
resolved (Prism 3130; ABI).
Statistical Analysis
We performed analysis of variance (ANOVA), with the post hoc Fisher
PLSD (protected least-significant difference) correction, using statisti-
cal software (Statview; SAS, Cary, NC). Results with P 	 0.05 were
considered statistically significant. Correlation analyses were per-
formed with Fisher-to-Z transformation of Pearson coefficients.
RESULTS
Patterns of central fundus changes, age of onset, disease dura-
tion, VA of the right and left eyes, and patterns of color vision
impairment as assessed by the anomaloscope are indicated in
Table 1. Central fundus changes were, in general, symmetric
across the patients’ eyes. In 5 (24%) of 21 families studied,
more than one sibling was affected. In these families, the
intrafamilial variability in age of onset was reduced, with a
maximum mean deviation of 2.4 years (average mean devia-
tion, 1.2 years). The pattern of central fundus alterations in
patients belonging to the same family was also very similar,
even when the estimated severity was not the same (Fig. 1).
Psychophysics
Color Psychophysical Tasks. Twenty-one patients with
STGD were tested with the anomaloscope, and only two were
found to have normal color vision. Tritan (76%) and protan
(62%) were the color anomalies more often found in our
patients, whereas deutan anomalies were less frequent (19%).
Alterations in more than one of the colorimetric equations
(Rayleigh and Moreland) were often detected (13/27 patients).
On the other hand, when we attempted quantitative charac-
terization of relative damage of each cone population through
a slightly modified version of Cambridge Color Test (CCT;
CRS), nine patients (who were not acuity limited for this
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specific test), with mean disease duration of 8.2  3.1 years
(VA: 0.1–0.8), were included. As shown in Figure 2, statisti-
cally significant impairment of all three cone channels was
observed in patients with STGD (P 	 0.0001 for protan, deu-
tan, and tritan axes; Fisher PLSD). However, in patients with
shorter disease evolution, more evident damage in protan and
deutan axes was found (protan: from mean 45.4  104 uv
units in control subjects to 350.0  104 in patients, P 	
0.0001; deutan: from 44.8  104 uv units in the normal
group to 409.1 104 uv in patients with STGD, P	 0.0001;
tritan: 63.5  104 uv units in control subjects to 185.2 
104 in patients, P 	 0.0001). No significant relation was
observed between disease stage and color vision deficiencies.
Relatives of patients with STGD were not significantly impaired
in this task, except for the tritan axis (103.6  104 uv units,
P  0.003).
CS Achromatic Psychophysical Tasks. Representative
maps of CS obtained for the two stimuli conditions (LSF and
ISF) from representative (close to the median) patients with
STGD, morphologically unaffected relatives, and control sub-
jects are shown in Figures 3 and 4. As expected from known
relative cone distributions, CS was higher in central locations
than in the more peripheral regions for both CS methods. The
LSF task yielded higher CS than did the ISF-task in all groups (in
age-matched control subjects mean CS was 29.4  3.4 dB in
the LSF-condition and 25.2  7.2 dB in the ISF perimetric
tests). Three patients with STGD were excluded (of 27) due to
unstable fixation.
LSF-biased perimetry revealed significant impairment in pa-
tients with STGD in comparison to their relatives and control
subjects (P 	 0.0001 for both comparisons). Of note, the
patients’ performance was significantly impaired across the
whole visual field and not only at the central-most regions (P	
0.0001 for zones 0, 1 and 2, for both CS methods). For the ISF
task the deterioration of CS function in patients with STGD was
even more evident (patients’ mean CS was 17.3  8.7 and
10.8  7.7 dB for the LSF and ISF tasks, respectively).
Concerning morphologically unaffected relatives, LSF pe-
rimetry showed, as expected, significantly better performance
than in patients with STGD for all tested zones (P  0.0008 for
zone 0; P 	 0.0001 for zones 1, 2). However, we were sur-
prised to find significant differences between these morpho-
logically unaffected relatives and control subjects across the
whole visual field (P 	 0.0013, P  0.0045, and P  0.0009,
for zones 0, 1 and 2, respectively). Again, similar results were
obtained with the ISF test (P 	 0.0187, P 	 0.0001, and P 
0.0012 for zones 0, 1, and 2, respectively). These asymptom-
atic relatives had CS performances that were between the
patients with STGD and the control group, for both CS tasks
(mean CS was 26.5 5.3 and 21.0 8.2 dB for the LSF and ISF
conditions, respectively). In summary, STGD relatives seem to
be relatively impaired in both CS tasks. In other words, mor-
phologically unaffected relatives might represent a pre-STGD
stage with CS impairment (also discussed later in the article).
Electrophysiological Recordings
Examples of mfERGs obtained from representative patients
with STGD, STGD morphologically unaffected relatives, and
age-matched control subjects are shown in Figure 5A.
FIGURE 1. Typical intrafamilial pat-
terns of variability of central fundus
changes in STGD families. (A) Sib-
lings belonging to family 14 with
more similar fundus changes are
shown. (B) Siblings from family 13
with moderate central fundus changes
and a distinct pattern.
FIGURE 2. Mean length of chromatic discrimination vectors (protan,
deutan, and tritan) were significantly increased in patients with STGD,
but the effect did not reach significance in STGD relatives, except for
the tritan axis (103.6  104 uv units; P  0.003).
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By comparison with relatives and age-matched control sub-
jects, patients with STGD showed significant smaller P1 ampli-
tudes, with the typical loss of the central retina peak (P 	
0.0001 for both comparisons to relatives and control subjects).
This amplitude reduction was strong and very significant for all
the eccentricity rings (P 	 0.0001 for all rings 1–5).
Of note, STGD morphologically unaffected relatives
showed further evidence for some degree of physiological
impairment, with P1 amplitudes significantly larger than pa-
tients and significantly smaller than control subjects. P1 ampli-
tudes in STGD relatives were significantly decreased in the
more central rings but not in the more peripheral ones com-
pared with age-matched control subjects (P  0.0043, P 
0.0016, and P  0.008 for rings 1, 2 and 3, respectively; NS for
rings 4 and 5).
Implicit times of the P1 component were analyzed for all
eccentricities. We observed that mfERG responses from pa-
tients with STGD were significantly delayed in the more ec-
centric rings compared with those of unaffected relatives and
control subjects (rings 3: P 	 0.02 and P  0.0035 for com-
parisons to relatives and control subjects; rings 4, 5: P 	
0.0001 for both comparisons). No significantly delayed re-
sponses were observed in the group of STGD relatives.
Correlations between Psychophysics,
Electrophysiology, and Disease Progression
To evaluate whether psychophysical and electrophysiological
measurements conveyed independent information, we per-
formed correlation analyses (with Fisher-to-Z transformation)
between LSF- and ISF-CS measures and P1 amplitudes. Corre-
lation analyses between corresponding areas revealed signifi-
cant correlations within 5° to 20° zones for the LSF but not for
the ISF sensitivity measures (correlation coefficient [cc] 
0.477 and P 0.03 for 5° to 10°, cc 0.431 and P 0.057 for
10° to 20° locations for LSF-task). To improve the statistical
power, we then correlated global CS performance obtained in
both LSF- and ISF- methods with P1 summed-amplitude re-
sponses and found significant correlations (LSF task: cc 
0.517 and P  0.018; ISF-task: cc  0.481 and P  0.043),
suggesting global level correlations between psychophysical
and electrophysiological responses and at least a partially com-
mon neural substrate.
No significant relation was observed between disease stage
and color vision deficiencies. However, performance in LSF,
ISF-CS tasks and P1 amplitude responses correlated highly with
disease stage, as revealed by ANOVA. Of interest, P1 amplitude
and LSF-CS were significantly impaired in the “moderate” dis-
ease stage compared with the “mild” stage (P  0.0033 for P1
amplitude and P  0.0059 for the LSF-CS task); however, a
further progressive deterioration to the “severe” stage was only
significant for CS tasks (P 	 0.0001 for both ISF- and LSF-CS
methods). These results extend the notion of progressive CS
impairment across stages once STGD is established. None of
the phenotypical methods applied showed any correlation
with disease duration, as indexed by the onset of decay in VA.
Genetic Characterization
In this study, we investigated ABCA4 mutations in asymptom-
atic relatives, where 12 (80%) of 15 subjects studied were
found to be carriers (Table 2). Twelve different putatively
disease-causing alterations were identified, including nine mis-
sense amino acid substitutions (75%), two frameshifts (16.7%),
FIGURE 3. CS in Stargardt families
obtained by the LSF testing method.
(A) Stimulus display for both CS
tests. (B) Maps of CS from represen-
tative individuals from the STGD
group, STGD relatives, and control
group. (C) CS at three zones of in-
creasing eccentricity obtained in the
three groups. Impairment of CS func-
tion was evident in patients with
STGD at all eccentricities. Surpris-
ingly, STGD relatives were also found
to be impaired in this LSF-CS task.
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and one splicing variant (8.3%). The most frequent mutation
found was the missense variant G1961E (6.7%) that, even in the
heterozygous state, has been significantly associated with age-
related macular degeneration (AMD).16 One missense mutation
involving an uncharged amino acid (L11P) in a conserved
domain that has been found in FFM patients was detected.
Several other sequence changes that have been significantly
correlated to the STGD phenotype (M1V, N96D, R290W,
L2027F, R2030Q, V2050L, 3211insGT, and IVS405G
A)
were also identified. Furthermore, two mutations were found
for the first time (M1T, 4034delAC) and were not present in
102 control chromosomes but in their respective STGD-
affected members. Both novel mutations may induce a se-
vere phenotype, since similar variations in the same codons
(missense M1V and insertion 4035insCA) are thought to be
STGD and CRD associated, respectively. Overall, five muta-
tions may be interpreted as null: the missense changes
affecting the initiation codon (M1V and M1T), two frameshift
alterations (3211insGT, 4034delAC), and one splice variant
(IVS405G
A). Only one subject (MCA) was found to carry a
complex allele. No ABCA4 mutation was detected in 6 (20%) of
30 studied alleles from relatives belonging to three STGD
families. Nevertheless, in two of these families, no ABCA4
mutation was identified in the affected family member.
In the case of subject CMD, relative with the homozygous
wild-type genotype, we confirmed the absence of the two
mutations detected in her affected sibling. As expected, we
observed in this case a relatively high performance in all psy-
chophysical tasks and robust physiological responses. (She was
at the 90 percentile for both psychophysical and electrophys-
iological measures, which was the expected result for this
negative control.) In addition, to exclude the possibility that
peripherin/RDS gene mutations were involved in such STGD
families with no ABCA4 mutation identified, we assessed mu-
tation analyses of the former gene by direct sequencing of
those families, and again no causal sequence change was iden-
tified (data not shown).
DISCUSSION
We have provided a topographic characterization of visual
impairment, using psychophysical and electrophysiological ap-
proaches, in patients with STGD, their morphologically unaf-
fected relatives, and unrelated control subjects. To our knowl-
edge, this is the first report describing physiological
impairment in STGD relatives with an apparently normal phe-
notype, as documented by a gold-standard ophthalmic exami-
nation, in which the ABCA4 mutation carrier state was as-
sessed. A recent study on multifocal pattern dystrophy
simulating STGD showed that asymptomatic family members
could show development of discrete retinal abnormalities.
However, in this previous report, an autosomal dominant in-
heritance pattern was identified, and mutations in peripherin/
RDS were causal,31 which was not the case in our study.
With our custom-made CS methods, we were able to show
that patients with STGD are dramatically impaired in their
sensitivity up to 20° of the visual field. The amount of CS loss
shown by patients with STGD was greatest at the highest
tested stimulus spatial frequency. Furthermore the most dra-
matic impairment was observed at eccentric locations for the
ISF task compared with the LSF condition. This finding of
different CS profiles across tests also suggests that the two
distinct types of gratings used show a different activation bias
concerning parvo- and magnocellular visual pathways.32,33 LSF
gratings flickering at 25 Hz favor the activation of magnocellu-
lar pathway, which is consistent with the higher CS that was
obtained with such stimuli. This finding is in accordance with
electrophysiological measures in primates, and this argument
has been used to justify its application in patients with glau-
coma to evaluate magnocellular damage.34–37 We speculate
that the ISF condition may better stimulate the parvocellular
visual pathway (at least compared with the more magno-like
LSF condition). Accordingly, the lower observed CS could
reflect the lower photoreceptor-bipolar-ganglion cell conver-
gence within the parvocellular pathway.38,39
FIGURE 4. CSF in subjects from STGD
families obtained by the ISF testing
method. (A) Maps of CS obtained
from representative individuals from
each group. (B) CS at three zones of
eccentricity obtained from the three
groups. Again, severe impairment in
CS function was observed in patients
with STGD at all eccentricities. STGD
relatives were again found to be im-
paired in this achromatic CS task.
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mfERG responses were globally correlated with psycho-
physical measures and were found to be dramatically impaired
across the retina of patients with STGD. Our results corrobo-
rate previous work in STGD where functional defects were
often not limited to the fovea and parafovea, but did affect
peripheral retina more than expected by more conventional
visual field measurements and ophthalmoscopy.40
Surprisingly, we found that morphologically nonaffected
STGD relatives with normal VA were functionally impaired as
revealed both psychophysical and electrophysiological ap-
proaches. Their visual performance, as measured by LSF and
ISF tasks was between normal age-matched control subjects
and patients with STGD.
Overall, 12 different mutations were identified in 80% of the
asymptomatic STGD, including two new putative severe mu-
tations (M1T, 4034delAC), which were segregated within the
STGD families. The only proven wild-type homozygous relative
(thereby serving as a negative control) was found to be at the
90th percentile for all phenotypical tasks.
A matter for future studies is a further investigation to
determine the extent that the genetical profiles of impaired but
morphologically unaffected relatives are related to the ones of
overtly impaired STGD subjects and why in the former case are
physiological alterations the sole manifestation of impairment.
It is worth noting that mutations in ABCA4 have a high prev-
alence in the general population (7%–8%)41,42 Furthermore,
previous studies have reported that residual ABCA4 activity
correlates with the severity of the clinical phenotype, as re-
flected by the age of onset. Another interesting finding is that
ABCA4 deficiency has been proved to cause or contribute to
the manifestations of several other autosomal recessive retinal
dystrophies—namely, cone–rod dystrophy, retinitis pigmen-
tosa, and a apparent susceptibility to age-related macular de-
generation (AMD), in both human and animal models.16,17,43
Therefore, we suggest that apparently normal carriers, at least
for some mutations, may have an insufficiency of ABCA4 ex-
pression. This hypothesis is corroborated by recent work of
Mata et al.,43 and Wiszniewski et al.44 who found that heterozy-
FIGURE 5. mfERG obtained from rep-
resentative individuals of patients
with STGD, STGD relatives, and con-
trol groups (A). Decreased mfERGs
responses were observed in patients
with STGD and relatives. (B) mfERG
peak amplitudes for the P1 compo-
nent were significantly reduced in
different eccentricity rings up to 30°.
(C) P1 amplitude responses across
the different rings correlated highly
with STGD disease stages (mild, mod-
erate, and severe).
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gous null mutations in the ABCA gene cause clinical signs that
resemble STGD but with slower progression. Thus, we believe
that relatives of persons with STGD should be followed-up,
because their visual function as a group is subnormal. Given
the similarity between STGD and AMD and that some high-
prevalence mutations—namely, the variant G1961E—even in
the heterozygous state, have been significantly associated with
AMD, STGD carriers may well have some predisposition to the
development of AMD, although this statement must at this
point remain speculative. Moreover, some evidence for in-
creased incidence of AMD in STGD families has been found.45
Future work on quantitative phenotyping and correlative
mutation analysis of ABCA4 in both patients with STGD and
relatives may be promising to help predict early functional
consequences of loss of ABCA4 activity that induces photore-
ceptor degeneration.
Acknowledgments
The authors thank the patients and their families for participating in
the study and Ana Rita Vaz, Ma´rio Soares, Pedro Melo, and Catarina
Mateus for technical assistance.
References
1. Stargardt K. U¨ber famila¨re, progressive Degeneration in der Macu-
lagegend des Auges. Graefes Arch Clin Exp Ophthalmol 1909;71:
534–550.
2. Kaplan J, Gerber S, Larget PD, et al. A gene for Stargardt’s disease
(fundus flavimaculatus) maps to the short arm of chromosome 1.
Nat Genet. 1993;5:308–311.
3. Irvine AR, Wergeland FL Jr. Stargardt’s hereditary progressive mac-
ular degeneration. Br J Ophthalmol 1972;56:817–826.
4. Blacharski PA. Fundus flavimaculatus. In: Newsom DA, ed. Retinal
Dystrophies and Degenerations. New York: Raven Press; 1988;
135–159.
5. Noble KG, Carr RE. Stargardt’s disease and fundus flavimaculatus.
Arch Ophthalmol. 1979;97:1281–1285.
6. Aaberg TM. Stargardt’s disease and fundus flavimaculatus: evalua-
tion of morphologic progression and intrafamilial co-existence.
Trans Am Ophthalmol Soc. 1986;84:453–487.
7. Armstrong JD, Meyer D, Shizhao X, Elfervig JL. Long-term fol-
low-up of Stargardt’s disease and fundus flavimaculatus. Ophthal-
mology. 1998;105:448–458.
8. Lois N, Holder GE, Fitzke FW, Plant C, Bird AC. Intrafamilial
variation of phenotype in Stargardt macular dystrophy-fundus fla-
vimaculatus. Invest Ophthalmol Vis Sci. 1999;40:2668–2675.
9. Fishman GA. Fundus flavimaculatus. Arch Ophthalmol. 1976;94:
2061–2067.
10. Delori FC, Staurenghi G, Arend O, Dorey CK, Goger DG, Weiter
JJ. In vivo measurement of lipofuscin in Stargardt’s disease-fundus
flavimaculatus. Invest Ophthalmol Vis Sci. 1995;36:2327–2331.
11. Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL, Hockey
RR. Variation of clinical expression in patients with Stargardt
dystrophy and sequence variations in the ABCR gene. Arch Oph-
thalmol 1999;117:504–510.
12. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific
ATP-binding transporter gene (ABCR) is mutated in recessive Star-
gardt macular dystrophy. Nat Genet. 1997;15:236–246.
13. Webster AR, Heon E, Lotery AJ, et al. An analysis of allelic variation
in the ABCA4 gene. Invest Ophthalmol Vis Sci. 2001;42:1179–
1189.
14. Shroyer NF, Lewis RA, Lupski JR. Complex inheritance of ABCR
mutations in Stargardt disease: linkage disequilibrium, complex
alleles, and pseudodominance. Hum Genet. 2000;106:244–248.
15. Rivera A, White K, Stohr H, et al. A comprehensive survey of
sequence variation in the ABCA4 (ABCR) gene in Stargardt disease
and age-related macular degeneration. Am J Hum Genet. 2000;67:
800–813.
16. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt
disease gene (ABCR) in age-related macular degeneration. Science.
1997;277:1805–1807.
17. Martinez-Mir A, Paloma E, Allikmets R, et al. Retinitis pigmentosa
caused by a homozygous mutation in the Stargardt disease gene
ABCR. Nat Genet. 1998;18:11–12.
18. van Driel MA, Maugeri A, Klevering BJ, Hoyng CB, Cremers FP
ABCR unites what ophthalmologists divide(s). Ophthalmic Genet.
1998;19:117–122.
19. Sun H, Nathans J. Stargardt’s ABCR is localized to the disc mem-
brane of retinal rod outer segments. Nat Genet 1997;17:15–16.
20. Molday LL, Rabin AR, Molday RS. ABCR expression in foveal cone
photoreceptors and its role in Stargardt macular dystrophy. Nat
Genet. 2000;25:257–258.
21. Scholl HPN, Kremers J, Vonthein R, White K, Weber BH. L- and
M-cone driven electroretinograms in Stargardt’s macular dystro-
phy-fundus flavimaculatus. Invest Ophthalmol Vis Sci 2001;42:
1380–1389.
TABLE 2. Pathogenic Variants of the ABCA4 Gene Found in Nonaffected Relatives
Family Subjects Phenotype CFC ABCA4 Allele 1/Allele 2
1 ARP No STGD (F) No changes N96D/wt
2 CAO No STGD (S) Subtle* Wt/wt
3 GMB No STGD (B) No changes IVS405G
A/wt
4 MAS No STGD (S) No changes 3211insGT/wt
5 MCA No STGD (M) No changes M1V R2030Q/wt
6 LCB No STGD (B) No changes R290W/wt
7 VCG No STGD (S) No changes L2027F/wt
8 JMF No STGD (B) No changes V2050L/wt
9 DRN No STGD (M) No changes M1T/ wt
10 SCR No STGD (S) No changes G1961E/wt
11 AGK No STGD (S) No changes L11P/wt
13 JLO No STGD (B) Subtle* G1961E/wt
14 GBR No STGD (F) No changes 4034delAC/wt
18 CMD No STGD (S) No changes Wt/wt
20 MLC No STGD (M) No changes Wt/wt
21 BRG No STGD (S) No changes ND
Family, nonaffected relative, phenotype, and relationship to the affected relative: F, father; M, mother;
B, brother; S, sister, CFC, central fundus changes and ABCA mutations detected; wt, wild-type. Novel
putative pathogenic variants are depicted in bold.
* Siblings CAO and JLO had subtle changes in their fundus but did not fulfill the criteria for Stargardt
disease.
1198 Maia-Lopes et al. IOVS, March 2008, Vol. 49, No. 3
22. Campos SH, Forjaz V, Kozak LR, Silva E, Castelo-Branco M. Quan-
titative phenotyping of chromatic dysfunction in Best macular
dystrophy. Arch Ophthalmol. 2005;123:944–949.
23. Castelo-Branco M, Faria P, Forjaz V, Kozak LR, Azevedo H. Early
and late damage of parvo- and koniocellular function in ocular
hypertension and glaucoma. Invest Ophthalmol Vis Sci 2005;45
(2):499–505.
24. Wyszecki G, Stiles WS. Color Science: Concepts and Methods:
Quantitative Data. 2nd ed. New York: John Wiley & Son; 1982.
25. Silva MF, Faria P, Regateiro FS, et al. Independent patterns of
damage within magno-, parvo- and koniocellular pathways in Par-
kinson’s disease. Brain 2005;128:2260–2271.
26. Mendes M, Silva F, Simoes L, Jorge M, Saraiva J, Castelo-Branco M.
Visual magnocellular and structure from motion perceptual defi-
cits in a neurodevelopmental model of dorsal stream function.
Brain Res Cogn Brain Res. 2005;25 (3):788–798.
27. Caprioli J. Automated perimetry in glaucoma. Am J Ophthalmol.
1991;111:235–239.
28. Hood DC, Seiple W, Holopigian K, Greenstein V. A comparison of
the components of the multifocal and full-field ERGs. Vis Neurosci.
1997;14:533–544.
29. Jaakson K, Zernant J, Kulm M. et al. Genotyping microarray (gene
chip) for the ABCR (ABCA4) gene. Hum Mutat. 2003;22:395–403.
30. Simonelli F, Testa F, de Crecchio G, et al. New ABCR mutations
and clinical phenotype in Italian patients with Stargardt disease.
Invest Ophthalmol Vis Sci 2000;41:892–897.
31. Boon CJ, van Schooneveld MJ, den Hollander AI, et al. Mutations in
the peripherin/RDS gene are an important cause of multifocal
pattern dystrophy simulating STGD1/fundus flavimaculatus. Br J
Ophthalmol 2007;91:1504–1511.
32. Alexander KR, Barnes CS, Fishman GA, Pokorny J, Smith VC.
Contrast sensitivity deficits in inferred magnocellular and parvo-
cellular pathways in retinitis pigmentosa. Invest Ophthalmol Vis
Sci. 2004;45:4510–4519.
33. Alexander KR, Rajagopalan AS, Seiple W, Zemon VM, Fishman GA.
Contrast response properties of magnocellular and parvocellular
pathways in retinitis pigmentosa assessed by the visual evoked
potential. Invest Ophthalmol Vis Sci. 2005;46:2967–2973.
34. Silveira LC, Yamada ES, Perry VH, Picanco-Diniz CW. M and P
retinal ganglion cells of diurnal and nocturnal New-World mon-
keys. Neuroreport. 1994;5:2077–2081.
35. Merigan WH, Maunsell JH. How parallel are the primate visual
pathways? Annu Rev Neurosci. 1993;16:369–402.
36. Dandona L, Hendrickson A, Quigley HA. Selective effects of ex-
perimental glaucoma on axonal transport by retinal ganglion cells
to the dorsal lateral geniculate nucleus. Invest Ophthalmol Vis Sci.
1991;32:1593–1599.
37. Maddess T, Goldberg I, Wine S, Dobinson J, Welsh AH, James AC.
Testing for glaucoma with the spatial frequency doubling illusion.
Vision Res. 1999;39:4258–4273.
38. Perry VH, Cowey A. The ganglion cell and cone distribution in the
monkey retina: implications for central magnification factors. Vi-
sion Res. 1985;25:1795–1810.
39. Yamada ES, Silveira LC, Perry VH, Franco EC. M and P retinal
ganglion cells of the owl monkey: morphology, size and photore-
ceptor convergence. Vision Res. 2001;41:119–131.
40. Kretschmann U, Seeliger MW, Ruether K, Usui T, Apfelstedt-Sylla
E, Zrenner E. Multifocal electroretinography in patients with Star-
gardt’s macular dystrophy. Br J Ophthalmol 1998;82:267–275.
41. Maugeri A, van Driel MA, van de Pol, et al. The 2588G3C muta-
tion in the ABCR gene is a mild frequent founder mutation in the
Western European population and allows the classification of
ABCR mutations in patients with Stargardt disease. Am J Hum
Genet. 1999;64:1024–1035.
42. Maugeri A, Flothmann K, Hemmrich N, et al. The ABCA4 2588G.C
Stargardt mutation: single origin and increasing frequency from
South-West to North-East Europe. Eur J Hum Genet. 2002;10:197–
203.
43. Mata NL, Tzekov RT, Liu X, Weng J, Birch DG, Travis GH. Delayed
dark-adaptation and lipofuscin accumulation in abcrþ/2 mice: im-
plications for involvement of ABCR in age-related macular degen-
eration. Invest Ophthalmol Vis Sci. 2001;42,1685–1690.
44. Wiszniewski W, Zaremba C, Yatsenko A, et al. ABCA4 mutations
causing mislocalization are found frequently in patients with se-
vere retinal dystrophies. Hum Mol Genet. 2005;14(19):2769–
2778.
45. Souied EH, Ducroq D, Gerber S, et al. Age-related macular degen-
eration in grandparents of patients with Stargardt disease: genetic
study. Am J Ophthalmol. 1999;128(2):173–178.
IOVS, March 2008, Vol. 49, No. 3 Retinal Dysfunction in Stargardt Disease 1199
